These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25971532)

  • 21. Perineural invasion and preoperative serum CA19-9 as predictors of survival in biliary tract cancer.
    Kawamata H; Yamashita K; Nakamura K; Katagiri H; Ishii K; Takahashi Y; Furuta K; Kumamoto Y; Watanabe M
    Anticancer Res; 2013 Feb; 33(2):583-94. PubMed ID: 23393352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
    Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
    Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrahepatic cholangiocarcinoma: a clinicopathologic study of 37 resected cases.
    Zhu HF; Li J; Huang L; Yan YQ
    Hepatogastroenterology; 2013; 60(122):263-7. PubMed ID: 23574653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
    Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
    J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials.
    Maisey NR; Norman AR; Hill A; Massey A; Oates J; Cunningham D
    Br J Cancer; 2005 Oct; 93(7):740-3. PubMed ID: 16175188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.
    Boeck S; Haas M; Laubender RP; Kullmann F; Klose C; Bruns CJ; Wilkowski R; Stieber P; Holdenrieder S; Buchner H; Mansmann U; Heinemann V
    Clin Cancer Res; 2010 Feb; 16(3):986-94. PubMed ID: 20103662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
    Takada T; Amano H; Yasuda H; Nimura Y; Matsushiro T; Kato H; Nagakawa T; Nakayama T;
    Cancer; 2002 Oct; 95(8):1685-95. PubMed ID: 12365016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
    Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
    Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical value of serum CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer].
    Zhu YB; Ge SH; Zhang LH; Wang XH; Xing XF; DU H; Hu Y; Li YA; Jia YN; Lin Y; Fan B; Ji JF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):161-4. PubMed ID: 22368025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are serum and biliary carcinoembryonic antigen and carbohydrate antigen19-9 determinations reliable for differentiation between benign and malignant biliary disease?
    Akdoğan M; Parlak E; Kayhan B; Balk M; Saydam G; Sahin B
    Turk J Gastroenterol; 2003 Sep; 14(3):181-4. PubMed ID: 14655062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer.
    Kim HJ; Lee KW; Kim YJ; Oh DY; Kim JH; Im SA; Lee JS
    Acta Oncol; 2009; 48(3):385-90. PubMed ID: 18855156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary sclerosing cholangitis with equivocal cytology: fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy.
    Barr Fritcher EG; Voss JS; Jenkins SM; Lingineni RK; Clayton AC; Roberts LR; Halling KC; Talwalkar JA; Gores GJ; Kipp BR
    Cancer Cytopathol; 2013 Dec; 121(12):708-17. PubMed ID: 23839915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CA19-9 serum concentrations--analysis of the serum kinetics during first-line therapy of pancreatic cancer in relation to overall survival.
    Klapdor R; Bahlo M; Babinski A; Klapdor S
    Anticancer Res; 2010 May; 30(5):1869-74. PubMed ID: 20592394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical value of serum CA19-9 as a prognostic factor for the ampulla of Vater carcinoma.
    Kurihara C; Yoshimi F; Sasaki K; Iijima T; Kawasaki H; Nagai H
    Hepatogastroenterology; 2013 Oct; 60(127):1588-91. PubMed ID: 23933785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biopathological characteristics of hilar cholangiocarcinoma and the clinical significance].
    Yu WL; Zhang YJ; Dong H; Yu H; Xian ZH; Wu MC; Cong WM
    Zhonghua Wai Ke Za Zhi; 2009 Aug; 47(15):1162-6. PubMed ID: 20021908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
    Li YG; Zhang N
    Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of serum carbohydrate antigen 19-9 for predicting extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma.
    Sasaki A; Kawano K; Inomata M; Shibata K; Matsumoto T; Kitano S
    Hepatogastroenterology; 2005; 52(66):1814-9. PubMed ID: 16334783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins.
    Sakamoto Y; Kosuge T; Shimada K; Sano T; Ojima H; Yamamoto J; Yamasaki S; Takayama T; Makuuchi M
    Surgery; 2005 Apr; 137(4):396-402. PubMed ID: 15800484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
    Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
    Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.